NECLIFE2024-10-012024-12-31 NECLIFE2024-10-012024-12-31 NECLIFE2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member NECLIFE2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member NECLIFE2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532649 NECLIFE NOTLISTED Nectar Lifesciences Limited Equity 2024-04-01 2025-03-31 2025-01-31 2025-01-24 INR Lakhs Third quarter 15:30:00 16:30:00 2025-01-31 2025-01-31 Not applicable Single segment PHARMACEUTICAL 2024-10-01 2024-12-31 Unaudited Consolidated 4549821000.00 5730000.00 4555551000.00 2941515000.00 0.00 378888000.00 245013000.00 171216000.00 156135000.00 537306000.00 4430073000.00 125478000.00 0.00 125478000.00 0.00 47074000.00 47074000.00 0.00 78404000.00 0.00 0.00 0.00 0.00 78404000.00 0.00 78404000.00 0.00 0.00 0.00 0.00 224261000.00 1 0.35 0.35 0.00 0.00 0.35 0.35 Notes: 1.The above financial results were reviewed by Audit Committee on January 31, 2025 and approved by the Board in its meeting held on January 31, 2025. The statutory auditors of the Company have conducted a “Limited Review” of the above standalone and consolidated unaudited financial results for the quarter and Nine Months ended on December 31, 2024. 2.The company is exclusively in the pharmaceutical business segment. 3.Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period. 4.The Company has one wholly owned subsidiary, namely NECLIFE PT, UNIPESSOAL LDA, which is Inoperative during the period ended on December 31, 2024. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 12423797000.00 18132000.00 12441929000.00 8450237000.00 0.00 204029000.00 726676000.00 569063000.00 466225000.00 1764389000.00 12180619000.00 261310000.00 0.00 261310000.00 0.00 97226000.00 97226000.00 0.00 164084000.00 0.00 0.00 0.00 0.00 164084000.00 0.00 164084000.00 0.00 0.00 0.00 0.00 224261000.00 1 0.73 0.73 0.00 0.00 0.73 0.73 Other Expenses 537306000.00 Other Expenses 1764389000.00